Results 61 to 70 of about 3,535 (191)

Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome

Continence
Mirabegron is a beta-3 adrenoceptor agonist for the treatment of overactive bladder syndrome. Our objective was to measure the risk of chorioretinal disease in new users of mirabegron compared to new users of anticholinergics.
Blayne Welk, Eric McArthur, James Armstrong, Cindy Hutnik   +3 more
doaj   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1500-1506, November 2026.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

Therapeutic Advances in Urology, 2017
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a similar prevalence of storage symptoms as women. The efficacy and safety of once-daily mirabegron 50 mg was evaluated in male OAB patients from five phase
Andrea Tubaro, José E. Batista, Victor W. Nitti, Sender Herschorn, Christopher R. Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke   +8 more
doaj   +1 more source

Effect of Mirabegron on Intraocular Pressure in Patients with Glaucoma

, 2020
Objective:Assessment of the effects of mirabegron treatment used for overactive bladder (OAB) symptoms in glaucoma patients on intraocular structures.Materials and Methods:One hundred-twenty six female glaucoma patients, who received mirabegron treatment
Ün, Emine Şeker, Sıtkı Ün, Emine Şeker Ün, Ün, Sıtkı   +3 more
core   +1 more source

Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response

, 2019
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Processo FAPESP: 2013/13907–4Processo FAPESP: 2017/15175–1Processo FAPESP: 2018/09765–3Mirabegron is the first β3-adrenoceptor agonist approved on the market and may offer beneficial ...
Bertollotto, Gabriela M., De Nucci, Gilberto, Pupo, André S. [UNESP], Candido, Tuany Z., Pupo, André S., de Oliveira, Mariana G., Kiguti, Luiz Ricardo de A., Antunes, Edson, Mónica, Fabíola Z., Rojas-Moscoso, Julio Alejandro   +9 more
core   +1 more source

Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials

Urological Science, 2015
Objective: Mirabegron, a β3-adrenoceptor agonist, has been shown to be effective and safe in the treatment of overactive bladder (OAB). The aim of this study was to assess the efficacy and safety of mirabegron (50 mg) versus placebo in Taiwanese patients
Hann-Chorng Kuo, Ho-Hsiung Lin, Hong-Jeng Yu, Chen-Li Cheng, Man-Jung Hung, Alex Tong-Long Lin   +5 more
doaj   +1 more source

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study

, 2021
Purpose: To compare the efficacy and tolerability of mirabegron and solifenacin in pediatric patients with idiopathic overactive bladder (OAB) and to identify factors affecting OAB symptom improvement after treatment.
전상현, 박명찬, 박세준, 김성철, 박성찬, 채종석, 문경현, 윤지형, 권택민   +8 more
core   +1 more source

Fibro‐Adipogenic Progenitors From Skeletal Muscle Enhance Microvascular Angiogenesis in a 3D Model

Advanced Biology, Volume 10, Issue 10, October 2026.
Fibro‐adipogenic progenitors (FAPs) are skeletal muscle stem cells that reside between fibers and near capillaries. However, relatively few studies have investigated interactions between FAPs and the microvasculature. We demonstrate that FAPs enhance angiogenesis of microvascular fragments (MVFs) by promoting increases in vessel percentage area and ...
Christian M. Mendiondo, Andrew R. King, Felipe Morales, David Leyton‐Cifuentes, Theodore J. Pabst, Eric M. Brey, Christopher R. Rathbone   +6 more
wiley   +1 more source

Brown Adipose Tissue: Molecular Mechanisms of Regulation, Physiological Functions, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
This review systematically covers three core dimensions of brown adipose tissue (BAT): multilayered regulatory mechanisms governing brown adipocyte differentiation and phenotypic identity, physiological functions and signaling pathways in mediating thermogenesis and systemic metabolic crosstalk between BAT and multiple organs, and emerging clinical in ...
Xiaoli Deng, Yuanyuan Shen, Ying Sun, Lu Lu, Chongkui Sun   +4 more
wiley   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source